2025
Daniel Drucker
Breakthrough Prize recognizes Daniel Drucker for work leading to diabetes, anti-obesity drugs
2025
Breakthrough Prize recognizes Daniel Drucker for work leading to diabetes, anti-obesity drugs
Few areas of biomedical research have had as immediate and far-reaching impact on global health as the work led by Dr. Daniel Drucker.
A University Professor at the University of Toronto’s Department of Medicine, Drucker works at the intersection of basic biology and clinical impact, his research focusing on how the human body controls metabolism and body weight through hormonal and molecular signals, particularly the hormone glucagon-like peptide-1 (GLP-1). By uncovering how GLP-1 functions in the body, his research has helped lay the foundation for therapies that address obesity and type 2 diabetes — conditions that place a growing strain on health systems worldwide.
At its core, Drucker’s research seeks to decode the body’s internal communication systems. By clarifying how these signals function, his research has triggered a new generation of life-changing treatments that control blood sugars, manage body weight and improve overall metabolic health.
Drucker’s work has been recognized by the international scientific community, reflecting the scale and durability of its impact. Over the years, he has received many of the world’s most respected honours in biomedical research — acknowledgements that signal how deeply his discoveries have reshaped modern understanding of metabolic diseases.
Dr. Daniel Drucker has translated fundamental discoveries into tangible therapies that are improving lives worldwide. Canadian biomedical research is once again recognized globally thanks to Dr. Drucker’s curiosity, expertise and a strong commitment to improving human health.
